Alps Advisors Inc. decreased its holdings in shares of GALAPAGOS NV/S (NASDAQ:GLPG) by 16.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 76,071 shares of the biotechnology company’s stock after selling 14,777 shares during the period. Alps Advisors Inc. owned approximately 0.15% of GALAPAGOS NV/S worth $6,979,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Financial Gravity Companies Inc. acquired a new position in GALAPAGOS NV/S during the fourth quarter worth $233,000. We Are One Seven LLC bought a new stake in shares of GALAPAGOS NV/S in the 4th quarter worth $27,000. FNY Investment Advisers LLC bought a new stake in shares of GALAPAGOS NV/S in the 4th quarter worth $458,000. Federated Investors Inc. PA grew its stake in shares of GALAPAGOS NV/S by 17.8% in the 3rd quarter. Federated Investors Inc. PA now owns 1,677,922 shares of the biotechnology company’s stock worth $188,648,000 after acquiring an additional 253,159 shares in the last quarter. Finally, Marshall Wace North America L.P. grew its stake in shares of GALAPAGOS NV/S by 258.1% in the 3rd quarter. Marshall Wace North America L.P. now owns 23,994 shares of the biotechnology company’s stock worth $2,697,000 after acquiring an additional 17,294 shares in the last quarter. Hedge funds and other institutional investors own 18.08% of the company’s stock.

Several analysts have recently issued reports on GLPG shares. Cantor Fitzgerald started coverage on shares of GALAPAGOS NV/S in a research note on Wednesday, December 19th. They issued an “overweight” rating and a $130.00 target price for the company. Nomura upped their target price on shares of GALAPAGOS NV/S from $124.00 to $140.00 and gave the stock a “buy” rating in a research note on Tuesday, October 30th. Zacks Investment Research lowered shares of GALAPAGOS NV/S from a “buy” rating to a “hold” rating in a research note on Friday, October 12th. Raymond James started coverage on shares of GALAPAGOS NV/S in a research note on Wednesday, November 14th. They issued a “strong-buy” rating and a $157.00 target price for the company. Finally, ValuEngine upgraded shares of GALAPAGOS NV/S from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 10th. Three analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. GALAPAGOS NV/S has a consensus rating of “Buy” and an average target price of $122.00.

GLPG opened at $101.53 on Friday. The stock has a market cap of $5.20 billion, a P/E ratio of -38.46 and a beta of 1.70. GALAPAGOS NV/S has a fifty-two week low of $85.00 and a fifty-two week high of $122.28.

COPYRIGHT VIOLATION WARNING: “Alps Advisors Inc. Lowers Holdings in GALAPAGOS NV/S (GLPG)” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.thecerbatgem.com/2019/02/09/alps-advisors-inc-lowers-holdings-in-galapagos-nv-s-glpg.html.

GALAPAGOS NV/S Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Recommended Story: Price-Sales Ratio

Institutional Ownership by Quarter for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.